OKYO Pharma Initiates Highly Dilutive $50M At-The-Market Offering to Fund Operations

summarizeSummary

OKYO Pharma Ltd. has launched an At-The-Market (ATM) offering to sell up to $50 million in ordinary shares, a move that could significantly dilute existing shareholders but is necessary to fund ongoing clinical development and operations amidst a 'going concern' warning.

check_boxKey Events

• Initiates $50M At-The-Market Offering

  OKYO Pharma has entered into a Sales Agreement with Leerink Partners LLC to offer and sell up to $50 million of its ordinary shares through an At-The-Market (ATM) offering. This finalizes terms and pricing of the offering initiated by the F-3 shelf registration filed on February 2, 2026.

• Substantial Dilution Potential

  The offering could result in the issuance of approximately 25.1 million new shares at an assumed price of $1.99 per share, representing a potential dilution of over 60% to current shareholders based on the 40.5 million shares outstanding as of February 9, 2026.

• Addresses Going Concern Warning

  The filing highlights that the company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern, and the proceeds from this offering are expected to provide funding for 'only a short period of time'.

• Proceeds for Clinical Development and Working Capital

  The net proceeds from the offering are intended for clinical development of product candidates, general corporate purposes, and working capital, indicating a critical need for operational funding.

auto_awesomeAnalysis

OKYO Pharma Ltd. has commenced a substantial At-The-Market (ATM) offering for up to $50 million in ordinary shares, following its universal shelf registration on February 2, 2026. This offering represents a potential dilution of over 60% of the company's current market capitalization, underscoring a critical need for capital. The proceeds are designated for clinical development and general corporate purposes, with the company explicitly stating that these funds are expected to sustain operations for only a short period. This financing is crucial for the company's continued operations, especially in light of its auditor's expressed doubt about its ability to continue as a going concern. While securing capital is vital, the significant dilutive impact highlights the company's precarious financial position despite recent positive clinical and regulatory milestones for its lead drug candidate, urcosimod.